Merck’s 2024 Adult Pneumonia Vaccine Faces Intensified Competition from Pfizer’s 25-Strain Pediatric Shot
Merck received FDA approval in 2024 for its adult pneumonia vaccine offering broader protection against severe infections. Pfizer’s experimental 25-valent pediatric shot generated a 15-fold higher antibody response against serotype 3 and targets 90% strain coverage, intensifying competition in the pneumonia market.
1. Merck’s 2024 Adult Pneumonia Vaccine Approval
Merck secured FDA approval in 2024 for its adult pneumonia vaccine, designed to protect against a broader range of bacterial strains linked to severe infections in older adults and at-risk populations.
2. Pfizer’s Next-Gen Pediatric Data
Pfizer’s mid-stage trial of a 25-valent pediatric vaccine demonstrated a 15-fold increase in antibody response against serotype 3 and aims to cover roughly 90% of disease-causing strains in children up to age five.
3. Intensified Competitive Dynamics
With Pfizer advancing its pediatric franchise and planning a 35-strain adult vaccine trial, Merck faces heightened competition in both adult and pediatric pneumonia markets where Prevnar generated over $6.5 billion in annual sales.
4. Strategic Implications for Merck
Merck may need additional label expansions, lifecycle management of its adult vaccine or new pipeline candidates to defend market share as Pfizer’s expanded vaccine offerings progress toward late-stage testing.